IO102
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for IO102, covering 2022-04-21 to 2026-04-08. Get the full timeline:
Most recent: Clinical Trial Update: IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC [Phase 2]